RESEARCH MONOGRAPH · KDC-MN-325

Palmitoylethanolamide (PEA)

May 9, 2026 Kodiac biolabs Research Revised May 30, 2026 3 min read

Our opinion on this compound

73/100

Underrated PPAR-alpha agonist with real but selective signal in chronic pain and neuroinflammation

PEA is one of the more underrated members of the broader endocannabinoid-adjacent family. It's not technically an endocannabinoid because it doesn't bind CB1 or CB2 with any meaningful affinity, but it's biosynthesized in the same on-demand fashion from membrane phospholipids and degraded by the same FAAH machinery, so the pharmacology overlaps in interesting ways.

Mechanism: primary target is PPAR-alpha (nuclear receptor) with additional indirect effects via what Aloe and Levi-Montalcini called the 'entourage effect,' meaning PEA competes for FAAH metabolism and effectively raises anandamide tone. Theres also weak GPR55 and GPR119 activity. The PPAR-alpha agonism drives most of the antiinflammatory phenotype.

The clinical evidence is meaningfully stronger than the wellness-industry framing might suggest. Italian groups have run multiple RCTs in chronic pain conditions (sciatica, fibromyalgia, diabetic neuropathy) using ultra-micronized formulations and shown consistent if modest effect sizes. Paladini and Coluzzi's pooled analyses are worth reading. The endometriosis pain literature is also positive. None of this is phase-3-Pfizer grade, but for a molecule that's been treated as a nutraceutical the trial base is honestly better than youd expect.

What people miss: bioavailability is everything. Plain crystalline PEA has lousy oral absorption because of particle size. The ultra-micronized and co-micronized formulations (PEA-um, PEA with polydatin or luteolin) actually move PK by orders of magnitude. Most of the negative trials have used unformulated bulk material. If you're doing in vivo work with PEA you need to think about formulation hard.

Sourcing: high-purity synthetic PEA is straightforward, the wholesale supply is generally clean, residual solvent QC is the main thing to check. For animal work the formulation matters more than the source.

What we like: well-mapped PPAR-alpha pharmacology, real clinical signal in chronic pain and neuroinflammation that doesn't depend on cannabinoid receptor binding, useful as a co-administration tool with FAAH inhibitors to amplify the anandamide arm.

What we dont like: the supplement-industry pricing on micronized formulations is honestly outrageous given what the molecule costs to produce, and the consumer narrative oversells the analgesic effect.

Real pharmacology, slept-on by the broader research community. Worth knowing the formulation considerations.

Evidence: 70
Mechanism: 75
Reliability: 65
Safety: 88
Sourcing: 80
Value: 65
Signal: 70
Staying power: 72

Plain-language summary Intrigue 64 / 100

Palmitoylethanolamide (PEA) is a fatty acid amide your body makes from membrane lipids, first identified in egg yolk in 1957 because of its anti-inflammatory effects. It does not bind cannabinoid receptors directly. Instead it activates the PPAR-alpha nuclear receptor, stabilizes mast cells (the immune cells that release histamine), and competes with anandamide for the FAAH enzyme, indirectly raising endocannabinoid tone. Decades of European clinical work, particularly in Italy, support its use for chronic pain, neuropathy, and sciatica, with a generally clean safety record and meaningful effect sizes. It is sold as a supplement in the US and as a registered medical food in parts of Europe. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Endogenous N-acylethanolamide (PPAR-alpha agonist)

An endogenous N-acylethanolamide; a PPAR-alpha agonist with anti-inflammatory and analgesic activity used as a supplement for pain and neuroinflammation.

Abstract

Palmitoylethanolamide (PEA; CAS 544-31-0; molecular formula C18H37NO2; molecular weight 299.49) is an endogenous N-acylethanolamide identified in 1957 in egg yolk and named for its anti-inflammatory effects. The compound is biosynthesized in mammalian tissues from phospholipid precursors and is degraded by N-acylethanolamine acid amidase (NAAA) and FAAH. Mechanism is multifactorial: PPAR-alpha agonism (the principal target, mediating anti-inflammatory and analgesic effects), GPR55 agonism, mast cell stabilization, and indirect entourage-style effects on endocannabinoid signaling (via competition for FAAH). Approved as a supplement (Normast, PeaPure) in several European countries for chronic pain, sciatica, and neuroinflammation; clinical trials show modest analgesic effects in chronic pain conditions. Plasma half-life is short (minutes to hours); micronized formulations (PEA-um) have substantially better bioavailability. Used as the canonical PPAR-alpha-active endogenous lipid in research.

Mechanism of action

PPAR-alpha agonist; GPR55 agonism; mast cell stabilization; FAAH competition (entourage effect on endocannabinoids).

Reported research dose ranges

Supplement 600 to 1200 mg in the published literature (micronized).

References

Lo Verme J, et al. The nuclear receptor peroxisome proliferator-activated receptor-alpha mediates the anti-inflammatory actions of palmitoylethanolamide. Mol Pharmacol 2005.
Petrosino S, Di Marzo V. The pharmacology of palmitoylethanolamide and first data on the therapeutic efficacy of some of its new formulations. Br J Pharmacol 2017.
Keppel Hesselink JM, Hekker TA. Therapeutic utility of palmitoylethanolamide in chronic pain syndromes. Pain Pract 2012.

Read the full monograph

The full reference document is available as a research-use-only PDF download. Note: PDFs for newly added compounds may take a few hours to propagate after this article was published.

KDC-MN-325

The full reference document is provided strictly for research use only. It reports research dose ranges from the published literature, not instructions for use in humans or animals.

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

Kodiac sells research compounds for investigative use only.

Palmitoylethanolamide (PEA)

Abstract

Mechanism of action

Reported research dose ranges

References

Read the full monograph

Quick actions

Categories

Help and policies

Abstract

Mechanism of action

Reported research dose ranges

References

Read the full monograph

Adjacent monographs